What That Actually Means — and How It Compares to PRP

One of the most common concerns patients raise before considering regenerative medicine is direct and understandable: if stem cell therapy works, why is it not FDA approved?

The concern is valid. However, the phrase “not FDA approved” is often misunderstood. It does not automatically mean a treatment is ineffective or unsafe. It means the therapy has not completed the specific regulatory pathway required for formal approval for a defined indication.

To understand this clearly, it helps to compare stem cell therapy with another widely used treatment in hospitals worldwide: platelet-rich plasma (PRP). PRP is routinely used in orthopedics, sports medicine, and dermatology. Yet PRP itself is not FDA approved as a drug for knee osteoarthritis, tendon injuries, or hair restoration. The regulatory nuance matters.

What Does “FDA Approved” Actually Mean?

The U.S. Food and Drug Administration (FDA) approves drugs and biologics for specific diseases after large, controlled clinical trials demonstrate safety and efficacy for a defined indication. Approval is not a general endorsement of a technology; it is indication-specific.

For example, a biologic may be approved for rheumatoid arthritis but not for lupus. That does not imply it cannot have biological activity in lupus. It means it has not completed the regulatory process for that particular use.

Stem cell therapies, particularly mesenchymal stem cells (MSCs), are regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps) in the United States. Only a limited number of stem cell-based products have received full FDA approval, such as hematopoietic stem cell transplants for blood disorders. Most MSC-based regenerative applications remain investigational or are delivered under specific regulatory pathways.

The FDA has issued clear guidance warning against clinics marketing unapproved stem cell products with exaggerated claims. This regulatory caution is appropriate and necessary for patient safety. However, lack of FDA approval does not automatically invalidate the underlying biology.

Is PRP FDA Approved?

Platelet-rich plasma is derived from a patient’s own blood and concentrated to deliver high levels of growth factors. It is widely used for musculoskeletal injuries, osteoarthritis, wound healing, and aesthetic procedures.

PRP itself is not FDA approved as a drug for most of these uses. Instead, the devices used to prepare PRP are FDA cleared. There is an important distinction between device clearance and drug approval. The centrifuge or preparation kit may be cleared for processing blood, but PRP as a therapeutic biologic injection for knee osteoarthritis does not have a formal FDA drug approval.

Despite this, PRP is widely used in hospitals and sports medicine centers worldwide. Clinical studies published in journals such as The American Journal of Sports Medicine and Arthroscopy show variable but often meaningful improvement in pain and function in mild to moderate osteoarthritis. Major orthopedic societies acknowledge PRP as a potential option, though they often describe the evidence as moderate or evolving rather than definitive.

The key point: PRP is not FDA approved as a drug for osteoarthritis, yet it is widely used based on biological plausibility and growing clinical evidence.

How Stem Cells Compare to PRP

Mesenchymal stem cells and PRP share certain conceptual similarities. Both aim to enhance the body’s natural repair processes rather than replace tissue surgically. Both are biologically active rather than mechanical interventions. Both have heterogeneous protocols, variable dosing strategies, and evolving evidence.

However, stem cells differ in several important ways. MSCs are living cells capable of immunomodulation, paracrine signaling, and homing toward inflamed tissue. They do not permanently engraft, but they release cytokines, growth factors, and extracellular vesicles that influence inflammation and tissue repair pathways. This mechanism has been described extensively in peer-reviewed literature, including Cell Stem Cell and Nature Medicine.

PRP, in contrast, delivers concentrated platelets and growth factors but does not contain living stem cells capable of adaptive immune modulation. Its activity is largely limited to growth factor release.

Both therapies face similar regulatory realities: neither is broadly FDA approved for degenerative joint disease, aging, or systemic inflammation as standard first-line treatments. Both are used in practice based on emerging clinical evidence and physician discretion.

Why Many Physicians Are Cautious

Physicians trained in conventional evidence-based medicine often rely heavily on treatments that have passed through large, randomized, phase III clinical trials. For MSC therapy in orthopedic and neurological indications, many studies remain phase I or phase II, with smaller patient populations.

This does not mean the therapy lacks biological validity. It means the regulatory pathway is still developing. Large-scale trials are expensive and time-consuming. Pharmaceutical companies often sponsor them for patent-protected drugs. Cell therapies, particularly allogeneic MSCs, operate under different economic and regulatory frameworks.

The same cautious attitude existed for PRP fifteen years ago. Initially viewed as experimental, PRP gradually became integrated into sports medicine as evidence accumulated. Stem cell therapy may follow a similar trajectory, but responsible medical practice requires careful patient selection and transparent discussion of limitations.

Thailand Regulatory Context

In Thailand, stem cell therapies are regulated under national medical and laboratory standards. Cultured stem cells must be processed in certified laboratories, and quality control measures such as sterility testing and cell viability assessment are required.

Regulation differs from FDA approval. A therapy may be legally and ethically administered within national medical frameworks without having U.S. FDA approval for a specific indication. Patients should understand the difference between regulatory compliance within a country and formal FDA drug approval.

Safety Considerations

Both PRP and MSC therapies have published safety data. Systematic reviews suggest that MSC therapy, when prepared and administered appropriately, is generally well tolerated, with most adverse events being mild and transient. However, serious complications have been reported in poorly regulated settings.

PRP is generally considered low risk because it is autologous, though infection, pain, or lack of efficacy are possible.

Patients should be cautious of clinics claiming guaranteed results or using language such as “cure.” Regenerative medicine aims to modulate inflammation and support repair, not to permanently eliminate disease in advanced stages.

Is Stem Cell Therapy “Coming”?

Clinical trials for MSC therapies are ongoing worldwide in orthopedics, autoimmune diseases, neurological conditions, and inflammatory disorders. Some cell-based products have already received regulatory approvals for specific uses in certain countries. Broader approvals depend on trial outcomes, manufacturing standardization, and regulatory frameworks.

About EDNA Wellness

EDNA Wellness is a private Stem Cell Clinic and Regenerative Medicine Center in Bangkok, Thailand, specializing in Umbilical cord–derived Mesenchymal Stem Cells (UC-MSCs) for knee osteoarthritis and joint pain, stroke and other neuro-related conditions, and stem cell IV infusions for longevity and healthy aging. All treatments are doctor-designed and performed in a sterile clinical setting

For more information or to book a consultation:

LINE: @ednawellness

WhatsApp: +66 (0) 64 505 5599

Website: www.ednawellness.com

Reference

• Pittenger MF, Discher DE, Peault BM, Phinney DG, Hare JM, Caplan AI. 2019. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regenerative Medicine.
• Lalu MM, McIntyre L, Pugliese C, et al. 2012. Safety of cell therapy with mesenchymal stromal cells (MSCs): A systematic review and meta-analysis of clinical trials. PLoS One.
• Furman D, Campisi J, Verdin E, et al. 2019. Chronic inflammation in the etiology of disease across the life span. Nature Medicine.